Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
1(33.3%)
Phase 3
1(33.3%)
Phase 4
1(33.3%)
3Total
N/A(1)
Phase 3(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02006693Phase 4Completed

Evaluation of the XEN Implant in Moderate Primary Open Angle Glaucoma (POAG) Participants

Role: lead

NCT02036541Not ApplicableCompleted

AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma

Role: lead

NCT01640756Phase 3Completed

AqueSys Microfistula Implant in Refractory Glaucoma

Role: lead

All 3 trials loaded